COVID-19 and COPD

Eur Respir J. 2020 Aug 13;56(2):2002108. doi: 10.1183/13993003.02108-2020. Print 2020 Aug.

Authors

Janice M Leung^{1

2}, Masahiro Niikura³, Cheng Wei Tony Yang¹, Don D Sin^{4

2}

Affiliations

¹ Centre for Heart Lung Innovation, University of British Columbia, Vancouver, BC, Canada.
² Division of Respiratory Medicine, Dept of Medicine, University of British Columbia, Vancouver, BC, Canada.
³ Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada.
⁴ Centre for Heart Lung Innovation, University of British Columbia, Vancouver, BC, Canada don.sin@hli.ubc.ca.

Abstract

COPD patients have increased risk of severe pneumonia and poor outcomes when they develop COVID-19. This may be related to poor underlying lung reserves or increased expression of ACE-2 receptor in small airways. https://bit.ly/37dSB8l

Publication types

Editorial
Review

MeSH terms

Aged
Airway Management / methods
Angiotensin-Converting Enzyme 2
Biomarkers / blood
COVID-19
Comorbidity
Coronavirus Infections / diagnosis
Coronavirus Infections / epidemiology*
Coronavirus Infections / therapy
Female
Global Health
Humans
Incidence
Male
Middle Aged
Pandemics / statistics & numerical data*
Peptidyl-Dipeptidase A / blood*
Pneumonia, Viral / diagnosis
Pneumonia, Viral / epidemiology*
Pneumonia, Viral / therapy
Pulmonary Disease, Chronic Obstructive / diagnosis
Pulmonary Disease, Chronic Obstructive / epidemiology*
Risk Assessment
Severity of Illness Index
Smoking / adverse effects
Smoking / epidemiology*
Vulnerable Populations

Substances

Biomarkers
Peptidyl-Dipeptidase A
ACE2 protein, human
Angiotensin-Converting Enzyme 2